Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells
Sponsor study identifier
interventional
59
1 country
2
Study Start
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2017
Actual (reported)Study Completion
December 2017
Actual (reported)The purpose of this study is:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2017
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
January 3, 2008
Actual (reported)February 3, 2009
Actual (reported)December 2017
Actual (reported)December 2017
Actual (reported)Primary toxicity endpoint
Incidence of delayed hematopoietic recovery and the incidence of Grade 3 or greater autoimmune events
2 yrs
ARM A = hTERT/GM-CSF+PCV, T cell infusion
ARM B GM-CSF+PCV, T cell infusion,GM-CSF+PVC
hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
Greenbaum Cancer Center
Baltimore, Maryland, 21201, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011 Jan 20;117(3):788-97. doi: 10.1182/blood-2010-08-299396. Epub 2010 Oct 28.
Carl H June, MD
University of Pennsylvania
59 participants (actual enrollment reported by the registry).
First Submitted
January 3, 2008
First Posted
February 3, 2009
Study Start
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
December 2017
Actual (reported)Study Completion
December 2017
Actual (reported)Last Updated
October 23, 2019
Record last verified: 2019-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: